论文部分内容阅读
目的观察雷公藤多苷片联合前列地尔注射液对糖尿病肾病患者血清白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)和肿瘤坏死因子-α(TNF-α)的影响。方法将90例糖尿病肾病患者随机分为A,B,C组,各30例。A组根据患者病史给予常规治疗;B组在A组的基础上静脉滴注前列地尔注射液10μg·d~(-1);C组在B组的基础上口服雷公藤多苷片60 mg·d~(-1),3组均连续治疗3个月。治疗后,观察3组患者的临床疗效及血清IL-6、hs-CRP、Hcy和TNF-α水平。结果治疗后,A,B,C组总有效率分别为63.33%(19/30例),80.00%(24/30例),90.00%(27/30例),B、C组与A组比较,差异有统计学意义(P<0.05)。治疗后,A,B,C组IL-6分别为(18.81±4.60),(15.53±3.40),(10.61±5.65)mg·L~(-1);hs-CRP分别为(9.49±3.52),(7.04±2.90)mg·L~(-1),(6.95±2.17)mg·L~(-1);Hcy分别为(24.83±4.83),(22.38±5.88),(14.15±7.79)mmol·L~(-1);TNF-α分别为(14.05±4.65),(13.17±2.21),(7.02±6.09)ng·L~(-1),3组IL-6、hs-CRP、Hcy和TNF-α与治疗前相比,差异均有统计学意义(P<0.05);且B、C组与A组比较,差异均有统计学意义(P<0.05)。3组治疗过程中均未出现恶心、呕吐、过敏、乏力等药物不良反应。结论雷公藤多苷联合前列地尔用于治疗糖尿病肾病患者,临床疗效显著,可明显降低IL-6、hs-CRP、Hcy和TNF-α水平。
Objective To observe the effects of Tripterygium wilfordii polyphenols tablets combined with alprostadil on serum interleukin 6 (IL-6), hs-CRP, homocysteine (Hcy) and tumor in patients with diabetic nephropathy Effect of necrosis factor-α (TNF-α). Methods 90 patients with diabetic nephropathy were randomly divided into A, B and C groups, 30 cases each. Group A received conventional treatment according to the patient’s medical history; Group B received 10 μg · d -1 of alprostadil intravenously on Group A; Group C received 60 μg of Tripterygium Wilfordii glycosides tablets on the basis of Group B · D ~ (-1), three groups were treated for 3 months. After treatment, the clinical efficacy and serum IL-6, hs-CRP, Hcy and TNF-α levels were observed in 3 groups. Results After treatment, the total effective rates in groups A, B and C were 63.33% (19/30 cases), 80.00% (24/30 cases) and 90.00% (27/30 cases), respectively , The difference was statistically significant (P <0.05). After treatment, the levels of IL-6 in A, B and C groups were (18.81 ± 4.60), (15.53 ± 3.40) and (10.61 ± 5.65) mg · L -1, respectively. The hs-CRP levels were (9.49 ± 3.52) (7.04 ± 2.90) mg · L -1 and (6.95 ± 2.17) mg · L -1, respectively, and Hcy were (24.83 ± 4.83), (22.38 ± 5.88), (14.15 ± 7.79) mmol · L -1 and TNF-α were (14.05 ± 4.65), (13.17 ± 2.21) and (7.02 ± 6.09) ng · L -1, respectively. The levels of IL-6, hs-CRP, (P <0.05). The difference between the two groups was statistically significant (P <0.05). The difference between the two groups was statistically significant (P <0.05). No adverse reactions such as nausea, vomiting, allergy, fatigue and other adverse drug reactions occurred in the three groups during the treatment. Conclusion Tripterygium glycosides combined with alprostadil for the treatment of diabetic nephropathy patients with significant clinical effects, can significantly reduce the levels of IL-6, hs-CRP, Hcy and TNF-α.